FcγRIIIa role in rituximab efficacy

Blood

Volumn 110, Issue 7, 2007, Pages 2220-

  Roda, Julie M ^a   Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CD20 ANTIBODY; FC RECEPTOR; RITUXIMAB;

ALLELE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B LYMPHOCYTE; BINDING AFFINITY; CELL ACTIVITY; CELL SURFACE; CELL VIABILITY; CORRELATION ANALYSIS; DRUG RECEPTOR BINDING; GENOTYPE; HUMAN; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NOTE; PRIORITY JOURNAL;

EID: 34948843605     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-05-090084     Document Type: Note

References (5)

1. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. 2000;6:443-446.
2. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005;11:5984-5992.
3. + lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood. Prepublished on April 17, 2007, as DOI 10.1182/blood-2006-12-062927.
4. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood. 2002;99:754-758.
5. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med. 2004;199:1659-1669.